Back to Awarded Treatment Trials
Awarded Trial: 02-STN-007
Grant ID
02-STN-007
Illness
Schizophrenia
Primary Drug/Intervention
Celecoxib
Primary Dosage
400 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Müller
Sample Size
50
Duration of Study Period for Each Subject
5 weeks
Outcome Measurements
PANSS, EPS scale
Results
In a trial with 50 patients, adjunctive treatment with this anti-inflammatory drug produced modest symptoms improvements. Two additional trials in schizophrenia and one in bipolar disorder are underway to further evaluate this treatment.
Publication
Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002 Jun;159(6):1029-34.
Link
http://www.ncbi.nlm.nih.gov/pubmed/12042193
PI Name
Norbert Müller
Degree
MD
Center
Department of Psychiatry
Institution
Ludwig-Maximilians Universitaet
Address
Nussbaumstr. 7
City or Town
Munich
State or Province
N/A
Zip or Postal Code
80336
Country
Germany
Email Address
norbert.mueller@med.uni-muenchen.de